Halifax-based MedMira has announced it has finished developing a serological Point-of-Care (POC) testing solution for COVID-19

The test, REVEALCOVID19, delivers immediate results without the need for additional equipment. It can be used with whole blood, serum or plasma and is ideal for batch testing in laboratory settings, thus meeting the needs of users across a broad range of testing environments, the company said in a statement.

MedMira is a developer and manufacturer of vertical flow rapid diagnostics (tests that combine liquids with reactive molecules to give a result). The company’s tests provide hospitals, labs, clinics and individuals with instant diagnoses of diseases such as HIV and Hepatitis C, the statement said.

“Our existing business is the development and sales of antibody tests for HIV and hepatitis, and we have internal lab and manufacturing facilities that are FDA certified and staffs who have been engaged in similar R&D for over 20 years,” said Hermes Chan, Medmira CEO.

The new test must obtain regulatory approvals before it can be sold.